We are the best strategic partner to lead innovative drugs
from EU approval to national P&R and Market Access in Spain,
specialised in oncology, orphan drugs and Advanced Therapies (ATMPs)

We are the best strategic partner to lead
innovative drugs from EU approval
to national P&R and Market Access in Spain,
specialised in oncology, orphan drugs
and Advanced Therapies (ATMPs)

neo2020-09-10T10:26:51+00:00

WHAT WE DO

We offer strategic support to companies during the drugs’ full lifecycle: from the regulatory process, including the Therapeutic Positioning Report (TPR) development to P&R submission, negotiation and approval, and Market Access at regional and hospital level. We do so by collaborating with relevant stakeholders, scientific societies and patients associations to ensure a successful Pricing and Market Access for innovative drugs in Spain.

OMAKASE LEADERSHIP TEAM

 ALICIA GIL
ALICIA GILPARTNER & CEO
XAVIER BADIA
XAVIER BADIAPARTNER & CEO

PUBLICATIONS

NEWS & EVENTS

Its now available the 4th edition of EDS Journal cotaining several articles about latest actuality. To highlight, there is an interesting entry about how to assess clinical benefit in order to accelerate access of innovative drugs where multidisciplinar experts have participated

November 17th, 2020|

Today at 1.30pm, Dr. Badía participates as an expert in the session “Cost, value and clinical benefit in the Oncology setting” to talk about  MCDA for evaluating and positioning cancer treatments.

November 13th, 2020|

GET IN TOUCH

CONTACT INFO

BARCELONA & MADRID OFFICES

Telephone: +34 674614704 | +34 931890969

E-mail: administracion@omakaseconsulting.com

APPLY FOR A JOB

Please send your CV to: administracion@omakaseconsulting.com

Follow Us On Social Media!

This website uses cookies so that you have the best user experience. If you continue browsing you are giving your consent for the acceptance of the aforementioned cookies and the acceptance of our cookies policy, Click on the link for more information. ACEPTAR

Aviso de cookies